RxDoctor Payments Data

Cody Horn

Infectious Disease · Chillicothe, OHNPI 1770945313

Payments from drug & device makers

$1,660in general payments, 2019–2025

Across 64 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$562
  • AstraZeneca$266
  • AbbVie$219
  • Dexcom, Inc.$147
  • Johnson & Johnson$139
  • Merck$90
  • plus $238 from 9 others

What the payments were for

  • Food & beverage$1,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,660 in reported general payments places this provider in the 65th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$153,017
Medicare patients
367
Services billed
1,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala36$144,688
Daptomycin63$127,825
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$50,924
TriumeqAbacavir/Dolutegravir/Lamivudi13$48,018
CeftriaxoneCeftriaxone Sodium37$11,195
Vancomycin Hcl41$11,026
Fosfomycin Tromethamine30$6,860
Cefepime Hcl22$5,635
ErtapenemErtapenem Sodium12$4,937
Voriconazole14$3,919
Itraconazole20$3,085
Doxycycline Monohydrate43$2,592
Doxycycline Hyclate46$1,244
Cephalexin30$1,017
Cefazolin Sodium13$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$562$195,61249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →